Morgan Stanley Maintains Equal-Weight on Zenas BioPharma, Raises Price Target to $22

Morgan Stanley analyst Judah Frommer maintains Zenas BioPharma (NASDAQ:ZBIO) with a Equal-Weight and raises the price target from $21 to $22.